Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-072 · 5 trials · 2 indications
Safety and tolerability assessment by the evaluation of vital signs, ECGs, physical exams, clinical lab testing and adverse event monitoring.
Single Dose Pharmacokinetic profile evaluation
| Arm | Type | Description |
|---|---|---|
| ABT-072 Tablet | ACTIVE_COMPARATOR | ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3 |
| Placebo | PLACEBO_COMPARATOR | Placebo Tablet, QD, single doses, groups 1-3 |
| 1 | EXPERIMENTAL | ABT-072 tablet single ascending dose |
| 2 | EXPERIMENTAL | Placebo tablet |
| 3 | EXPERIMENTAL | ABT-072 tablet administered under non-fasting conditions. |
| 4 | EXPERIMENTAL | ABT-072 tablet administered under fasting conditions |
| 5 | EXPERIMENTAL | ABT-072 tablet multiple ascending dose |
| Tablet 1 vs. Capsule | ACTIVE_COMPARATOR | Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid. |
| Tablet 2 vs. Capsule | ACTIVE_COMPARATOR | Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid. |
| Name | Type | Description |
|---|---|---|
| ABT-072 | DRUG | See arm description for more information |
| Placebo | DRUG | See arm description for more information |
| ketoconazole | OTHER | Tablet, see Arm Description for intervention information. |
Inclusion Criteria: * Overall healthy adult Japanese males Exclusion Criteria: * Use of any medications (prescription and over-the-counter), vitamins, or herbal supplements within the 2-week period prior to the first dose of study drug administration or within 10 half-lives of the respective medi...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
ABT-072 is an investigational small molecule being developed for the treatment of Hepatitis C and HCV Infection. It is intended for use in patients with these conditions, although it is still in clinical development and has not been approved by regulatory authorities.
ABT-072 is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT. The drug is in Phase 1 clinical development for the treatment of Hepatitis C and HCV Infection.
ABT-072 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety, tolerability, and pharmacokinetic profiles in humans.
ABT-072 has completed four Phase 1 clinical trials, including NCT00752687, NCT00890318, NCT00982826, and NCT01081483. These trials evaluated the drug in healthy volunteers and patients with Hepatitis C, with a total enrollment of 194 participants across the United States and Japan.
ABT-072 is a distinct investigational compound developed by Abbott Laboratories. No alternative names for this drug have been identified in the available information, and it is not known to be the same as any other marketed or investigational medication.